{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-199409","form_type":"8-K","ticker":"BAX","cik":"0000010456","company_name":"BAXTER INTERNATIONAL INC","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.005848+00:00","generated_at":"2026-05-31T09:33:46.637196+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Baxter agrees to sell Kidney Care segment (Vantive) to Carlyle for $3.8B cash","bullets":["Baxter to receive ~$3.5B in cash; net after-tax proceeds ~$3B; to be used for debt reduction.","Transaction expected close late 2024 or early 2025, subject to regulatory approvals.","Vantive had 2023 revenue of $4.5B and 23,000 employees; Chris Toth to remain as CEO.","Baxter targets 4-5% constant currency operational sales growth post-divestiture; adjusted operating margin ~16.5% for 2025.","Baxter expects to reach below 3.0x leverage by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-199409","json":"https://secwatch.observer/filing/0001193125-24-199409.json","markdown":"https://secwatch.observer/filing/0001193125-24-199409.md","text":"https://secwatch.observer/filing/0001193125-24-199409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10456/000119312524199409/0001193125-24-199409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10456/000119312524199409/d878887d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:33:46.637196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d4caac2397","claim":"Chris Toth departed as Executive Vice President and Group President, Kidney Care at BAXTER INTERNATIONAL INC.","evidence_excerpt":"Chris Toth will cease serving as Executive Vice President and Group President, Kidney Care, and as an executive officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000119312524199409/0001193125-24-199409-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"cease serving"},{"label":"Role","value":"Executive Vice President and Group President, Kidney Care"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}